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Purpose: To investigate the effects of topical FTY720 and cyclosporin A (CsA) on allogeneic corneal transplantation in
mice.
Methods: A total of 75 BALB/c mice received corneal grafts from C57BL/6 donors. Recipients were treated with 0.1%,
0.3%, or 0.5% FTY720 ophthalmic gel or 1% CsA eye-drops after the graft (controls received no treatment). The number
of cluster of differentiation (CD)4+ T cells and CD4+CD25+forkhead box P3 (Foxp3)+ regulatory (Treg) cell phenotypes
were measured by flow cytometry. Cytokine mRNA expression in corneal grafts was analyzed by real-time quantitative
PCR. CD4 + T cells and cytokines in corneal samples were identified by immunohistochemical staining.
Results: Corneal graft survival was prolonged by treatment with topical 0.5% FTY720 (mean survival time [MST],
24.1±1.6 days) or 1% CsA eye-drops (MST 25.0±1.9 days) compared with controls (MST, 13.4±0.5 days; n=9, both
p<0.01). Topical 0.5% FTY720 treatment significantly increased the percentages of CD4 + T (p<0.05) and Treg cells
(p<0.01; n=5) in the cervical lymph nodes compared with controls. Transforming growth factor-β1 (TGF-β1) mRNA
transcription  in  corneal  grafts  after  topical  0.5%  FTY720  increased  (p<0.05,  n=3),  while  interleukin-2  (IL-2)  and
interferon-γ (IFN-γ) mRNA expression in corneal grafts treated with 1% CsA decreased (p<0.01, p<0.05, respectively).
These cytokine results were paralleled by similar immunohistochemical staining. Topical 0.5% FTY720 and 1% CsA
treatment reduced the infiltration of CD4+ Tcells in the grafts.
Conclusions: Topical 0.5% FTY720 and 1% CsA can effectively prolong allogeneic corneal graft survival in mice.
Treatment with topical 0.5% FTY720 increases the percentage of CD4+ T cells and the percentage of Treg cells in cervical
lymph nodes. The 0.5% FTY720 increased TGF-β1 mRNA expression and decreases infiltration of CD4+ T cells in corneal
grafts, while topical 1% CsA down-regulated the expression of IL-2 and IFN-γ.
Corneal diseases are the second most important cause of
blindness  [1].  Some  of  these  cornea  conditions,  such  as
inflammation or infection, can be treated with medication.
Severe cases that are not treatable with medication, or in cases
where there is scarring or cloudiness of the cornea that results
in visual loss, may require corneal transplantation to improve
vision.  Corneal  transplantation,  known  as  penetrating
keratoplasty, is one of the most common and successful forms
of solid organ transplantation in humans [2]. Williams et al.
reported  that  the  probability  of  penetrating  corneal  graft
survival in the whole cohort was 87%, 73%, 60%, and 46% at
1, 5, 10, and 15 years respectively [3]. In addition, in high-risk
grafts that have either received a previous corneal transplant
or  prevascularized  graft  beds,  the  success  rate  fell
dramatically to be as low as 20% to 40% [4-6]. Irreversible
immune rejection of the transplanted cornea is the major cause
of  human  allograft  failure  in  the  intermediate  and  late
postoperative period [7]. Corneal graft-rejection is a complex
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immune process consisting of a sequence of events. Corneal
allograft rejection requires the presence of T lymphocytes
(likewise  called  T  cells),  and  cluster  of  differentiation
(CD)4+T  cells  are  the  most  important  T  cell  population.
Additionally, two ocular antigen presenting cell populations
— corneal Langerhans cells and conjunctival macrophages —
are also required [8]. In recent years, some studies reported
that  corneal  allograft  survival  was  associated  with
CD4+CD25+forkhead box P3 (Foxp3)+ T regulatory (Treg)
cells [9,10].
Currently available immunosuppressive drugs, such as
corticosteroids and cyclosporin A (CsA), are used to prevent
or  treat  corneal  graft  rejection  in  humans,  but  long-term
survival of corneal grafts, especially in high-risk recipients,
have not been entirely efficacious [11,12]. As a synthetic
structural  analog  of  myriocin,  FTY720  is  a  potent
immunosuppressant that can prolong allograft survival [13].
Once it is phosphorylated in vivo by sphingosine kinase 2
(SphK2), FTY720-P acts as an agonist on four of the five
known  sphingosine-1-phosphate  (S1P)  receptors  (S1P1,
S1P3,  S1P4,  and  S1P5)  [14].  In  contrast  to  classical
immunosuppressants, it has been shown that FTY720 does not
interfere  with  T-cell  proliferation,  but  induces  a  severe
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624deprivation of lymphocytes in the blood due to modification
of  S1P  signaling  [15].  A  multicenter,  dose-finding  study
compared the effectiveness of FTY720 plus full-dose CsA
(FDC),  FTY720  plus  reduced-dose  CsA  (RDC),  and
mycophenolate mofetil (MMF) plus FDC in de novo renal
transplant patients. The study found that 5 mg FTY720 in
combination with RDC or 2.5 mg FTY720 combined with
FDC  showed  comparable  rejection  prophylaxis  and
acceptable tolerability at 12 months compared with MMF plus
FDC [16]. Recently, Li et al. [17] found that the single use of
FTY720 can be effective to prolong the graft in rat cardiac
transplantation  model.  Sedláková  et  al.  [18]  found  that
intraperitoneal  injections  of  FTY720  could  prolong  graft
survival in rat-to-mouse corneal xenografts. Other two studies
also  found  that  oral  immunosuppression  with  FTY720
significantly prolonged corneal allografts [19,20]. However,
systemic FTY720 treatment was reported to cause nonfatal
herpesvirus  infections,  bradycardia  and  atrioventricular
block,  hypertension,  macular  edema,  skin  cancer,  and
elevated liver-enzyme levels [21]. To avoid the side-effects
of systemically administered immunosuppressant, we tested
the topical use of FTY720 and CsA in a mouse allogeneic
corneal transplantation model over a one- month period.
METHODS
Animals: Orthotopic corneal transplantation was performed
with inbred BALB/c and C57BL/6 male mice. Mice used in
grafting experiments weighed 18–22 g. C57BL/6 mice served
as donors and BALB/c mice were recipients of the corneal
allograft.  These  are  fully  mismatched  for  major
histocompatibility  complex  and  multiple  minor
histocompatibility antigens between the two inbred mouse
strains.  Mice  were  obtained  from  the  Beijing  HFK  Bio-
Technology.  Co.,  Ltd.  Beijing,  China.  All  animals  were
treated in accordance with the Association for Research in
Visio and Ophthalmology Statement on the Use of Animals
in Ophthalmic and Vision Research.
Orthotopic allogeneic corneal transplantation: A total of 75
BALB/c mice received corneal grafts from C57BL/6 donors
were randomized into a control group and four experimental
groups.  Before  all  surgical  procedures,  mice  were  deeply
anesthetized  by  an  intraperitoneal  injection  of  3%
pentobarbital sodium (80 mg/kg; Nembutal; Beijing Chemical
Co.,  Beijing,  China).  A  tropicamide-phenylephrine
ophthalmic solution (Santen Pharmaceutical Co., Ltd, Japan)
was topically applied to dilate the pupil of both the donors and
recipients. The donor cornea was prepared according to the
“underwater technique” originally described by Zhang et al.
[22]. The central 2.0 mm of a C57BL/6 cornea was marked
with a 2.0 mm trephine, excised with Vannas scissors and
placed  into  a  balanced  salt  solution  (BSS™;  Alcon,  Fort
Worth, TX) before grafting. The donor corneal graft was
sutured into a 1.5 mm BALB/c recipient corneal bed with 8–
10 interrupted 11–0 nylon sutures (Sharpoint, Reading, PA).
The anterior eye chamber was restored at the end of surgery
by injecting air. Corneal sutures were removed on day 10 after
transplantation.  Mice  that  received  in  situ  ophthalmic  gel
without any drugs (i.e., only a gel base) served as controls.
One  experimental  group  of  mice  received  CsA  eye-drops
(10 mg/ml; 1%; North China Pharmaceutical Group Co., Ltd.
Hebei, China) after transplantation. Other three experimental
groups of mice were treated in situ with an ophthalmic gel of
FTY720 (provided by the Department of Molecular Drug
Design, Institute of Pharmacology and Toxicology Sciences,
Beijing, China.) at doses of 1 mg/ml (0.1%), 3 mg/ml (0.3%),
and  5  mg/ml  (0.5%),  respectively,  after  transplantation.
Ophthalmic  gel  was  applied  twice  a  day  and  eye-drops
administered four times a day from day 0 (post-operation) to
day 30 (the end of study).
Clinical evaluation of grafted corneas: The degree of opacity
as well as the degree of neovascularization was evaluated
daily  until  day  14  and  then  three  times  a  week  for  the
remaining two weeks. Briefly, donor corneal opacity score (0–
4), edema score (0–2), and neovascularization score (0–4)
were graded according to criteria previously described [23].
Rejection was defined as the day on which indices of opacity,
edema, and neovascularization reached moderate or severe
levels, with an opacity score ≥3 and a total ≥5, in grafts that
were  initially  transparent  [23].  Grafts  with  technical
difficulties such as intraocular hemorrhage or infection were
excluded.  Six  mice  in  each  group  were  sacrificed  for
laboratory examination on day 14 after transplantation. An
additional nine mice in each group were observed for survival
time. At the time of rejection or the end of the study, mice
were sacrificed.
Flow cytometric analysis: The T cell phenotype in the right
cervical lymph node, peripheral blood, and the spleen of five
mice in each group were analyzed by flow cytometry on day
TABLE 1. PRIMER SEQUENCES USED FOR QPCR.
Gene Primer 1 (Forward, 5′→3′) Primer 2 (Reverse, 5′→3′)
GAPDH TGAAGGTCGGTGTGAACGGATTTG GTTGAATTTGCCGTGAGTGGAGTC
IL-2 GCACCCACTTCAAGCTCCA AAATTTGAAGGTGAGCATCCTG
IL-10 TGCCTTCAGCCAGGTGAAGACTTTC CTTGATTTCTGGGCCATGCTTCTCTG
TGF-β1 ATACCAACTATTGCTTCAGCTCCACAG GTACTGTGTGTCCAGGCTCCAAATAT
IFN-γ GCACAGTCATTGAAAGCCTAGAAAGTC GGTAGAAAGAGATAATCTGGCTCTG
Foxp3 ATGCCCAACCCTAGGCCAGCCAAG TGGGCCCCACTTCGCAGGTCCCGAC
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62514 after transplantation. Treg cells were detected by a Mouse
Regulatory T cell Staining Kit (PE Foxp3 FJK-16s, FITC
CD4,  APC  CD25)  from  eBioscience  (San  Diego,  CA),
according  to  the  manufacturer's  instructions.  Data  was
acquired  using  a  FACS  Calibur  flow  cytometer  (BD
Biosciences, San Jose, CA), and analyzed with Winmid 2.9
software (Scripps Institute, La Jolla, CA). The cells were
gated on lymphocytes, further gated for CD4+, and are shown
as the percentage of CD4+ T cells and CD4 + CD25 + FoxP3
+T cells.
Real time quantitative PCR: Three corneas in each group were
excised (2.5 mm in diameter), frozen in liquid nitrogen, and
stored at −80 °C on day 14 after transplantation. For intragraft
gene expression analysis, total cellular RNA was isolated
using the TRIzol® reagent (Invitrogen, Carlsbad, CA) and
liquid nitrogen. Reverse transcription of mRNA to cDNA was
performed in 20 μl reaction volumes with random priming and
EasyScript RT using Easy RT–PCR Kit (Beijing TransGen
Biotech  Co.  Ltd,  Beijing,  China).  Gene  expression  was
examined in an iCycler IQ Real-time PCR Detection System
(Bio-Rad, Hercules, CA) using the SYBR Green Realtime
PCR Master Mix (TOYOBO, Osaka, Japan) with respective
real-time quantitative PCR (qPCR) primers for interleukin-2
(IL-2),  IL-10,  transforming  growth  factor-β1  (TGF-β1),
Figure  1.  Prolongation  of  corneal
allograft  survival  by  topical
administration. Allograft survival of the
control  versus  topical  0.1%  FTY720
were not significantly different (p=0.47;
n=9) but was compared with the topical
0.3% FTY720 treatment group (p=0.03;
n=9). Treatment with 0.5% FTY720 or
1% CsA also resulted in significant graft
survival  compared  to  controls  (both
p<0.01;  n=9)  or  0.3%  FTY720
treatment  (p=0.02  and  p=0.01,
respectively). There was no significant
difference between 0.5% FTY720 and
1% CsA (p=0.51).
Figure 2. Opacity, edema and neovascularization of corneal grafts were observed. A: Ccontrol group on postoperative day 14. B: Topical 1%
CsA group on postoperative day 30. C: Topical 0.1% FTY720 group on postoperative day 14. D: Topical 0.3% FTY720 group on postoperative
day 14. E: Topical 0.5% FTY720 group on postoperative day 30.
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626Foxp3,  and  glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) [24,25]. The primers used are listed in Table 1. The
cycle number at which the reporter fluorescence reached a
threshold (CT value) was used for quantitative measurement.
The relative expression data was determined by normalizing
to GAPDH expression measured contemporaneously from the
same sample to calculate a fold-change in value using the
2−ΔΔCT method.
Histopathological  examination:  Fourteen  days  after
transplantation, the other three corneas in each group were
fixed in 10% formaldehyde solution, paraffin-imbedded, and
sectioned at 3 µm. Slides were deparaffinized and stained with
hematoxylin and eosin for histological examination of the
pathology, or processed for immunohistochemical analysis.
After deparaffinization, the slides were rehydrated, and heat-
induced  antigen  retrieval  was  performed.  Then
Figure 3. Flow cytometric analysis of the T cell phenotype in the right cervical lymph node, peripheral blood, and spleen. A: Flow cytometry
of the spleen of control mouse 2 on postoperative day 14. Gate 1: lymphocytes (R1, indicated in red). B: CD4+T cells (R2. Indicated in green)
in lymphocytes. C: Double labeling CD25+/Foxp3+ lymphocytes in CD4+ T population. Gate 2: R1 and R2.
Figure 4. The percentage of CD4+ T cells in the lymphocyte population in each group (%,) on postoperative day 14. The percentage of CD4+
T cells in the peripheral blood lymphocyte population (A), cervical lymph nodes (B), and spleen (C). Values represent mean±SD, n=5 mice/
group, *p<0.05 versus the control group. D: Flow cytometry showing the distribution of CD4+ T cells in lymph nodes.
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627immunostaining was performed using the following primary
antibodies,  Anti-CD4  Mouse  monoclonal  (mAb51312;
Abcam,  Cambridge,  UK),  anti-IFN  Gamma  (Biorbyt,
Carrickfergus, UK), IL-2, IL-10, and TGF-β1 (Santa Cruz
Technologies, Santa Cruz, CA); a horseradish peroxidase -
conjugated  goat  anti-mouse  immunoglobulin  G  (H+L)
(Zymed Laboratories, San Francisco, CA) was used as the
secondary antibody. Incubation with the diaminobenzidine
(DAB) chromogen for 5 min was used to visualize positive
staining (brown staining) followed by counterstaining with
Mayer’s hematoxylin for 1 min. PBS replaced the primary
antibody  as  a  negative  control.  Photographs  of  the  same
anatomic area- the central zone of each graft of each slide were
used for comparison. The positive stained cells were counted
on these the photographs.
Statistical  analysis:  Actuarial  graft  survival  was  analyzed
with the Kaplan–Meier survival method, and the log-rank test
was used to examine statistical differences among the groups.
A One-way ANOVA followed by multiple comparisons with
least significant difference (LSD) test was used in all other
cases. A p value <0.05 was considered significant.
RESULTS
Orthotopic  allogeneic  corneal  transplantation:
Transplantation  of  C57BL/6  corneal  grafts  to  BALB/c
recipients resulted in a rejection rate of 100% within a mean
survival time (MST) of 13.4±0.5 days (n=9) in the control
group, which was not statistically significant different from
the 0.1% FTY720 ophthalmic gel group (MST 14.0±0.7 days;
p=0.47; Figure 1). Although the rejection rate was also 100%
with 0.3% FTY720 treatment (MST 16.9±1.7 days), graft
survival  was  prolonged  when  compared  with  the  control
group (p=0.03). Treatment with either 0.5% FTY720 (MST
24.1±1.6  days)  or  1%  CsA  (MST  25.00±1.91  days)
significantly prolonged the period before rejection compared
to 0.3% FTY720 gel treatment (p=0.02, 0.01, respectively,
versus  control  p<0.01)  and  did  not  reach  100%  rejection
within  the  30  days.  The  corneal  allografts  being  rejected
exhibited pronounced opacity, edema and neovascularization
on postoperative day 14 (Figure 2A,C,D). As shown in Figure
2B,E, the corneal allografts seen after treatment with 1% CsA
or 0.5% FTY720 exhibited a clear stroma at the end of study.
Flow  cytometric  analysis:  Figure  3  shows  an  illustrative
example of how the determination was performed by flow
cytometry data. There were no significant differences in the
mean percentage of CD4 + T cells in the peripheral blood
samples (peripheral blood lymphocytes, PBLs) or the spleens
of mice within the five groups (p>0.05, n=5; Figure 4A,C).
Similarly, there were no statistical differences among the five
groups  (p>0.05,  Figure  5A,C)  in  the  mean  percentage  of
CD4+CD25+Foxp3+ T cells in the CD4 + T population of the
PBLs or spleen. The mean percentage of CD4 + T cells in
cervical lymph nodes of the 0.5% FTY720 ophthalmic gel
group was higher than the control group and 1% CsA group,
Figure 5. The percentage of CD4+CD25+Foxp3+ T (Treg) cells in the CD4+ T cell population in each group (%,) on postoperative day 14.
The percentage of Treg cells in the peripheral blood lymphocyte population (A), cervical lymph nodes (B), and spleen (C). Values represent
mean±SD, n=5 mice/group, *p<0.05 versus the control group. D: Flow cytometry showing the distribution of double CD25+Foxp3+ T cells
in the CD4+ T cell population in the lymph nodes.
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628respectively (p=0.04 and p=0.02, respectively, n=5; Figure
4B,D). There were also significantly higher percentages of
CD4+CD25+  Foxp3+  T  cells  in  CD4+  T  population  in
cervical lymph nodes after 0.5% FTY720 treatment versus the
control group or 1% CsA group respectively (both p<0.01,
Figure 5B,D).
Real-time quantitative PCR: The results of mRNA expression
in corneal grafts are shown in Figure 6. When compared with
the  control  group,  real-time  quantitative  PCR  analysis
demonstrated a significant reduction of IL-2 and IFN-γ mRNA
expression following topical application 1% CsA (p<0.01 and
p=0.04, respectively, n=3; Figure 6A,C). Although the levels
of IL-10 mRNA expression in the corneal graft after topical
0.3% and 0.5% FTY720 treatment were slightly higher than
those  seen  in  the  control  group,  there  were  no  statistical
differences among the five groups (p>0.05, n=3; Figure 6B).
Compared  with  the  control  group,  TGF-β1  mRNA
transcription  in  corneal  grafts  with  topical  0.5%  FTY720
increased (p=0.04, Figure 6D). An increase in Foxp3 mRNA
expression in the corneal grafts of the 0.5% FTY720 treatment
group was observed, but differences among the five groups
were not statistically significant different (p>0.05, Figure 6E).
Histopathological examination: Histopathological analysis of
the enucleated formalin fixed corneal grafts of the BALB/c
mice showed signs of graft rejection in the five groups 14 days
after corneal transplantation (Figure 7). The allografts in the
control  and  topical  0.1%  FTY720  groups  (Figure  7A,C,
respectively) revealed a heavy infiltration of inflammatory
cells, edema, and disruption of the stromal architecture. There
was  less  infiltration  of  inflammatory  cells,  and  edema
following the topical application of 1%CsA or 0.5% FTY720
(Figure 7B,E, respectively) compared with the control group.
Immunohistochemical staining showed that a large number of
CD4+ T cells (brown) had infiltrated the allograft in control
and topical 0.1% FTY720 groups (Figure 7F,H, respectively).
In  contrast,  no  significant  infiltration  of  CD4+  cells  was
observed in allografts after topical application of 1% CsA or
0.5% FTY720 (Figure 7G,J, respectively). In agreement with
the results of mRNA expression, the levels of IL-2 and IFN-
γ  protein  immunohistochemical  staining  in  corneal  grafts
were reduced after topical application of 1% CsA (Figure 8B-
Figure 6. The relative changes in cytokine mRNA expression in the corneal grafts. Values are given relative to an increase or decrease from
the control value in each group (mean±SD, n=3 mice/group) at postoperative day 14. *p<0.05 versus the control group. (A) IL-2, (B) IL-10,
(C) INF-γ, (D) TGF-β1, (E) Foxp3.
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629L). The immunohistochemical staining results indicated that
TGF-β1 protein in the allografts after topical 0.5% FTY720
was higher than that seen in control group (Figure 8P,T).
There were no apparent differences in the staining levels of
IL-10 protein in the allografts among the five groups (Figure
8F-J).
DISCUSSION
Corneal allotransplantation is the most common form of solid
tissue transplantation in humans and is characterized by a high
success rate of graft survival, but immunological rejection
remains a serious risk factor for corneal graft failure [4-8,
26]. Immunosuppressants, such as CsA and FK506, are now
used for prevention of allograft rejection in clinical corneal
transplantation. Although systemic CsA has clear therapeutic
efficacy, it is limited by the potential systemic side-effects
[27]. Topical CsA has been used and studied extensively with
regard to the management of corneal graft rejection in recent
years, but there were still some contradictory results [28-32].
As  a  new  immunosuppressant,  systemic  treatment  with
FTY720 can prolong corneal graft survival, but there are some
side-effects  [16-18,21].  Nevertheless,  FTY720  can  be
dissolved in DMSO and water [33], and can also be used for
topical application.
We  found  that  0.5%  FTY720  ophthalmic  gel  can
effectively prolong the survival of mouse corneal allografts.
Although Unal et al. [32] and Poon et al. [30] reported that
topical 0.05% CsA had no significant effect on corneal graft
survival, Alalwani et al. [28] found that 2% CsA in eye-drops
could effectively inhibit corneal rejection. In agreement with
these authors, we also found that topical application of 1%
CsA in eye-drops effectively prolonged corneal graft survival.
We do not find any statistically significant difference in
the  percentage  of  CD4+  T  cells  in  PBLs  among  the  five
groups.  The  reason  for  this  may  be  that  the  systemic
absorption after topical drug application is limited. The flow
cytometric  analysis  showed  that  there  was  a  statistically
significant difference in the percentage of CD4+ T cells in the
cervical  lymph  nodes  when  using  topical  0.5%  FTY720
(versus untreated animals) and is in agreement with studies
showing that FTY720 induced inhibition of T cells egress
from lymphoid organs due to modification of S1P [13,15].
Similar to that of the systemic therapy, topical 0.5% FTY720
reduced egress of lymphocytes from the lymph nodes and
stimulated CD4+ T cells of the cornea to home to the cervical
lymph nodes. And as is commonly known, CD4+T cells are
the  most  important  T  cell  population  involved  in  corneal
allograft rejection. Therefore, we suggest that topical 0.5%
FTY720  prolongs  corneal  allograft  survival  through  a
decrease in the number of CD4+ T cells in the cornea.
We  found  that  topical  0.5%  FTY720  significantly
enhances the percentage of CD4+CD25+foxp3+ T cells in the
cervical  lymphoid  nodes  followed  by  the  change  of  the
CD4+T cell distribution. This may be because FTY720 can
increase the percentage of Treg cells in the lymph nodes by
means  of  the  S1P  receptor.  It  has  been  reported  that
CD4+CD25+ Treg cells expressed lower levels of mRNA for
S1P1  and  S1P4  receptors  and  demonstrated  a  reduced
chemotactic response to S1P [34]. Additionally, FTY720 can
be phosphorylated in vivo by SphK2 to FTY720-P, which acts
as a potent S1P receptor agonist [14]. These results are in line
with  some  studies  showing  that  systemic  FTY720  can
significantly increase the percentage of Treg cells [35,36].
CD4+CD25+Foxp3+ Treg cells are a functionally distinct
subset of T cells with suppressive ability and prevent allograft
rejection  [9,10].  Matsuoka  et  al.  [37]  found  that  CD4+
lymphopenia was a critical factor in Treg cell homeostasis,
and  that  prolonged  imbalance  of  Treg  cell  homeostasis
resulted in a loss of tolerance and significant clinical disease
manifestations.  Moreover,  some  studies  had  shown  that
homing  of  Treg  cells  into  the  draining  lymph  nodes  was
required for the suppressive function of these cells [38,39].
Figure 7. Histopathology of corneal grafts. Examples of grafts stained with hematoxylin-eosin on postoperative day 14 (A-E, Magnification,
20×). A: Untreated corneal graft (control). B: Topical application of 1% CsA. C-E: Topical application of 0.1% 0.3% or 0.5% FTY720,
respectively. Examples of grafts showing CD4 positive staining (brown) on postoperative day 14 (F-J, Magnification, 40×). F: Untreated
corneal graft (control). G: Topical application 1% CsA. H-J: Topical application of 0.1% 0.3% or 0.5% FTY720, respectively.
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630Therefore, the specific suppressive function of topical 0.5%
FTY720  on  corneal  transplantation  can  be  explained  by
significantly increasing the percentage of Treg cells in the
cervical  lymph  nodes.  We  did  not  find  any  statistical
difference in the percentage of CD4+ T and Treg cells in the
1% CsA group, confirming that topical 1% CsA can not affect
the distribution of these cells.
To investigate further the mechanism by which topical
0.5%  FTY720  prolongs  corneal  allograft  survival,  we
analyzed the intra-graft mRNA gene expression of cytokines.
Although topical 0.5% FTY720 can change the Treg cell
distribution, we found that TGF-β1 mRNA expression (and
corneal  immunohistochemical  staining)  in  this  group  was
higher than that in the other groups. Several studies have found
that Treg cells can produce TGF-β1 and Treg cell suppression
was associated with TGF-β1 [40,41]. Based on these results,
we  suggest  that  topical  0.5%  FTY720  may  significantly
enhance the immune function of Treg cells by increasing
levels of TGF-β1 in the cornea. Moreover, we also found that
Foxp3  mRNA  expression  after  topical  0.5%  FTY720  is
slightly higher (albeit not significantly) compared with the
other groups. It has been clearly shown that the forkhead
family transcription factor, Foxp3, is critically important for
the  development  and  function  of  regulatory  T  cells  [42].
Therefore, we further hypothesize that topical 0.5% FTY20
significantly enhances the immune activity of corneal Treg
cells. The enhanced suppressive immune function of Treg
cells can reinforce the inhibition in the rejection of allogeneic
corneal transplants.
We found a significant decrease in IL-2 and IFN-γ mRNA
expression after topical application of 1% CsA, which was
also seen as reduced immunohistochemical staining in corneal
grafts compared with the control group. These results are
concordant  with  the  other  studies  showing  that  CsA
suppresses T cell proliferation by inhibiting the synthesis of
IL-2 and IFN-γ [43-45].
In  summary,  our  results  confirm  that  topical  0.5%
FTY720 or 1% CsA can effectively prolong mouse allogeneic
corneal graft survival for a one-month period. Topical 0.5%
FTY720 and 1% CsA have different pathways involved in the
suppression of corneal graft rejection. FTY720 increases the
percentage of CD4+ T cells and a raises the percentage of Treg
cells  in  cervical  lymph  nodes.  In  addition,  topical  0.5%
FTY720  enhances  the  immune  function  of  Treg  cells  by
increasing  TGF-β1  mRNA  and  protein  expression,  and
decreaseing CD4+ T cell infiltration into the corneal allograft.
Figure 8. Cytokine Immunohistochemical staining in corneal grafts on postoperative day 14. A, F, K, and P: Untreated corneal graft (control).
B, G, L, and Q: Topical 1% CsA group. C, H, M, and R: Topical 0.1% FTY720 group. D, I, N, and S: Topical 0.3% FTY720 group. E, J,
O, and T: Topical 0.5% FTY720 group. The brown staining represents positive IL-2 protein (A-E), positive IL-10 protein (F-J), positive IFN-
γ protein (K-O), and positive TGF-β1 protein (P-T).
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631Unlike topical 0.5% FTY720, topical 1% CsA inhibits CD4+
T cell proliferation and decreases the expression of IL-2 and
IFN-γ in the corneas. However, we did not find that topical
FTY720 and CsA completely inhibited the rejection of the
corneal allograft.
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